NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Lykiri, if you are correct and there were 28 methylated and 33 unmethylated GBM patients in the crossover group and those numbers are added to the 90 known methylated and 131 known unmethylated treatment patients, we have therefore a total of 118 methylated and 164 unmethylated GBM patients accounted for.

If of about 22 of the first 38 patients whose methylation status was by now deciphered, about 10 were methylated and 12 were unmethylated, we would
now have a total of 141 methylated (131+10=141) and 174 unmethylated patients (162+12=174).

That would mean that there are about 23 methylated GBM patients in the group of 35 permanent placebos (141-118=23) and only 10 unmethylated patients in that group (174-164=10) and that would account for the success of this group.
I guess the OS of the 23 methylated patients in that group will be measured against the OS of the treatment, crossover and ECAs separately. The same holds for the 10 methylated patients in the permanent placebo group.

If all this is true, I am somewhat disappointed because that means that the 64 crossovers were not as successful as I thought they would be.

However, I still don't understand why once they progressed, none of the 35 placebos received DCVax-L. Also it is very peculiar to end up with 35 placebos with more than twice as many methylated as unmethylated GBM patients. Go figure.

I will now review the links that Lykiri sent me.





However, I still don't understand why once they did progress, none of the 35 placebos received DCVax-L.